Exciting Developments at MBX Biosciences Amid Key Event

Author: Kelly Martin Updated: 09-29-2025 09:09 AM

MBX Biosciences Engages in Major Virtual Forum

MBX Biosciences, Inc. (NASDAQ: MBX), a company dedicated to creating innovative precision peptide therapies for endocrine and metabolic disorders, has confirmed its participation in a significant upcoming event. The firm's President and CEO, Kent Hawryluk, alongside Chief Medical Officer, Dr. Sam Azoulay, will partake in a fireside chat during the Stifel 2025 Virtual Cardiometabolic Forum.

Details of the Stifel 2025 Virtual Cardiometabolic Forum

This much-anticipated event is set to take place on September 30. The key highlights for the presentation include:

Forum Highlights

Date: Tuesday, September 30
Format: Fireside chat
Time: 10:00 a.m. – 10:25 a.m. ET
Location: Virtual

Those interested can access the live webcast via the events section on MBX's official website. A replay of the discussion will be accessible shortly after the event's conclusion and will remain available for about three months.

Understanding MBX Biosciences' Pursuits

MBX Biosciences specializes in pioneering biopharmaceutical advancements focused on addressing critical health challenges. They anchor their development efforts on a proprietary platform aimed at crafting precision peptide therapies tailored for endocrine and metabolic conditions.

Pipeline Overview

The company is currently advancing a promising pipeline targeting unmet medical needs with several pipeline candidates. These include:

Canvuparatide (MBX 2109): In Phase 2 development for chronic hypoparathyroidism (HP).
Imapextide (1416): Currently in Phase 2 for post-bariatric hypoglycemia (PBH).
Obesity Portfolio: This includes MBX 4291, which is in Phase 1, alongside multiple discovery and pre-clinical candidates aimed at obesity-related conditions.

The Importance of Their Mission

MBX Biosciences seeks to make a significant impact on patient health by developing therapeutics that cater to substantial medical gaps in the treatment of metabolic and endocrine disorders. Their strategic focus on clinically validated targets showcases their commitment to not just meeting but exceeding expectations in the biopharmaceutical sector.

Company Background and Contact Information

Based in Carmel, Indiana, MBX Biosciences is at the forefront of biopharmaceutical innovation. Those wishing to learn more about their endeavors can visit their website.

Contact Details

Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
Email: katie.beach@inizioevoke.com
Phone: (937) 232-4889

Investor Contact:
Jim DeNike
MBX Biosciences
Email: jdenike@mbxbio.com

Frequently Asked Questions

What is the focus of MBX Biosciences?

MBX Biosciences concentrates on discovering and developing precision peptide therapies for endocrine and metabolic disorders.

When is the Stifel 2025 Virtual Cardiometabolic Forum?

The forum is scheduled for September 30, and MBX Biosciences will participate in a fireside chat during the event.

How can I watch the MBX Biosciences presentation?

You can access the live webcast of the presentation through the events section of MBX's official website.

What are some key products in MBX's pipeline?

Notable products include MBX 2109 for chronic hypoparathyroidism and imapextide for post-bariatric hypoglycemia.

Where is MBX Biosciences located?

MBX Biosciences is based in Carmel, Indiana.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.